A multicenter open label study to compare efficacy and safety of induction treatment by thymoglobulin (ATG) versus daclizumab (anti-IL-2R) with a triple drug regimen (tacrolimus, mycophenolate mofetil, prednisone) in high risk renal transplant recipients.

Trial Profile

A multicenter open label study to compare efficacy and safety of induction treatment by thymoglobulin (ATG) versus daclizumab (anti-IL-2R) with a triple drug regimen (tacrolimus, mycophenolate mofetil, prednisone) in high risk renal transplant recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Daclizumab (Primary) ; Mycophenolate mofetil; Prednisone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms TAXI
  • Most Recent Events

    • 08 Jul 2011 New source added and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12610000071022).
    • 12 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top